Tumor-antigen-specific regulatory T cell (TAA-specific Treg)

Tumor-antigen-specific regulatory T cells (Tregs) are a specialized subset of CD4+ T lymphocytes that recognize antigens expressed by tumor cells and function to suppress the anti-tumor immune response within the tumor microenvironment (Sakaguchi et al., Nature Reviews Cancer, 2010). These cells are characterized by the expression of the transcription factor FOXP3 and high levels of the IL-2 receptor alpha chain (CD25), and they play a critical role in maintaining self-tolerance and preventing autoimmunity under normal physiological conditions (Plitas et al., Immunity, 2016). In the context of malignancy, these Tregs preferentially accumulate in the tumor tissue, where they inhibit the activation and proliferation of effector T cells (Teffs) and natural killer (NK) cells through the secretion of inhibitory cytokines like IL-10 and TGF-beta, as well as through direct cell-to-cell contact (Togashi et al., Nature Reviews Clinical Oncology, 2019). Therapeutic targeting of these cells aims to alleviate immunosuppression and enhance the efficacy of cancer vaccines and checkpoint inhibitors. Current pharmacological approaches include the use of monoclonal antibodies to deplete Tregs via antibody-dependent cellular cytotoxicity (ADCC) or to block their recruitment and suppressive signaling pathways (Tanaka & Sakaguchi, JCI, 2017). However, the primary challenge in targeting this population is achieving selectivity for tumor-infiltrating Tregs over systemic Tregs to avoid widespread autoimmune complications.

Other names

Tumor-specific regulatory T cellsTumor-infiltrating regulatory T cellsTAA-specific TregsTumor-associated antigen-specific Tregs

Therapeutic strategies involve the depletion of these cells via antibody-dependent cellular cytotoxicity (ADCC), inhibition of their recruitment to the tumor microenvironment by blocking chemokine receptors like CCR4, or the functional neutralization of their suppressive activity through checkpoint blockade.